|
|
|
Oxaliplatin
|
 |
| |
|
Oxaliplatin is a third generation platinum analog. Its activity and toxicity profiles differ from both cisplatin and carboplatin, and, thus, it lacks cross-resistance with these compounds. Oxaliplatin contains a bulky carrier ligand, 1,2-diaminocyclohexane (DACH), not present in either cisplatin or carboplatin. Oxaliplatin has a large spectrum of antineoplastic activity, including colorectal cancer, ovarian cancer, pancreatic cancer, non-Hodgkin's lymphoma, breast cancer, lung cancer, prostate cancer, germ-cell carcinomas, and malignant mesothelioma. It has been used in combination with a variety of other chemotherapy agents including 5-fluorouracil (5-FU) plus leucovorin (LV), irinotecan, raltitrexed, paclitaxel, cisplatin, and cyclophosphamide. The combination of oxaliplatin with 5-FU has been shown to be synergistic in 5-FU resistant advanced colorectal cancer and in first-line therapy of metastatic colorectal cancer.
Oxaliplatin’s innovator is Sanofi Aventis-Global and appears world-wide under the brand name Eloxatin. |
|  |
| |
|
|
|
|
Oxaliplatin is a non-cell cycle specific, alkylating antineoplastic agent that inhibits DNA synthesis. Oxaliplatin contains a bulky carrier ligand, 1,2-diaminocyclohexane (DACH), that determines the chemical reactivity and cytotoxicity of the platinum compound and influences the tissue distribution of the molecule. Oxaliplatin undergoes non-enzymatic conversion in blood and plasma to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo-, monochloro-, dichloro-, and diaquo-DACH platinum, which covalently bind with various blood components or intracellular macromolecules. Potentially lethal bifunctional DNA-protein-Platinum (Pt) cross-links and inter- and intra-strand Pt-DNA cross-links are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-gaunines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. As compared to cisplatin, oxaliplatin produces fewer DNA cross-links and is less able to form these cross-links.
Tumor cell resistance mechanisms to platinum compounds include reduced accumulation in cells, increased DNA repair mechanisms (e.g., changes in mismatch repair and enhanced replicative bypass), inactivation by conjugation with glutathione or sequestration involving metallothionine, and enhanced tolerance to platinum-DNA adducts.
Oxaliplatin appears in the following formulation and dosage:
Powder for IVInjection – 50,100mg/ vial |
 |
|
|
|
|
Other products, in the group of CNS PREPARATIONS - Antidepressant - Selective serotonin reuptake inhibitors available on TAPI's portfolio are:
Duloxetine Hydrochloride, Fluoxetine Hydrochloride, Fluvoxamine Maleate and Sertraline Hydrochloride. Contact us today for information on these products.
Legal Note
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).
*TAPI stands for Teva's Active Pharmaceutical Ingredients
|
|
|
|
| TAPI'S ACTIVE PATENTS/APPLICATIONS |
|
| |
|
|
|
|
2008 Available DMF: U.S. DMF and EU CTD.
TAPI provide full service on Oxaliplatin and other APIs in our portfolio. Our local sales offices provide full information on our product, regulatory compliance and documentation on Oxaliplatin. Contact us today for further inquiries and samples and kilograms availability information for TAPI's Oxaliplatin.
Other products, in the group of ANTINEOPLASTIC AGENTS - Alkylating agents available on TAPI's portfolio are : Carboplatin, Cisplatin, Sorafenib and Thiotepa. Contact us today for information on these products.
Legal Note
Product exploitation, including development, sales and offer for sale are performed where permissible by patent law. This presentation is not and should not constitute an offer for sale in territories where it is not permitted by law. In USA Products that Currently on Patent are available for R&D Use in Accordance with 35 USC §271 (e) (1).
*TAPI stands for Teva's Active Pharmaceutical Ingredients
|
|
|
|
|
